VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-12 |
2024-06 |
0 |
N/A |
N/A |
N/A |
2024-05-15 |
2024-03 |
-0.53 |
N/A |
N/A |
N/A |
2024-04-01 |
2023-12 |
-0.22 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.14 |
N/A |
N/A |
N/A |
2023-08-14 |
2023-06 |
-2.16 |
N/A |
N/A |
N/A |
2023-05-15 |
2023-03 |
-2.27 |
N/A |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2019-06-13 |
ANDERSON DAVID EVANDER |
Officer |
148.21K |
Conversion of Exercise of derivative security |
2019-09-29 |
BAXTER JEFFREY ROYSTON |
Chief Executive Officer |
608.26K |
Purchase |
2021-12-02 |
BEATTIE NELL |
Officer |
68.20K |
Purchase |
2019-06-13 |
DEWILDE MICHEL |
Director |
50.00K |
Conversion of Exercise of derivative security |
2019-10-03 |
DIAZ-MITOMA FRANCISCO |
Officer |
0.00 |
Purchase |
2023-07-09 |
GILLIS STEVEN |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Perceptive Advisors Llc |
1.38M |
4.54M |
6.04% |
2023-06-29 |
Blackrock Inc. |
112.15K |
368.96K |
0.49% |
2023-06-29 |
Cambridge Investment Research Advisors Inc. |
100.37K |
330.21K |
0.44% |
2023-06-29 |
Millennium Management Llc |
89.21K |
293.48K |
0.39% |
2023-06-29 |
Morgan Stanley |
77.98K |
256.54K |
0.34% |
2023-06-29 |
Geode Capital Management, LLC |
67.19K |
221.05K |
0.29% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
General American Investors Co |
62.58K |
205.90K |
0.27% |
2023-06-29 |
Vanguard Extended Market Index Fund |
59.71K |
196.44K |
0.26% |
2023-05-30 |
Fidelity Extended Market Index Fund |
31.33K |
93.04K |
0.14% |
2023-05-30 |
Schwab Strategic Tr-Schwab U.S. Small Cap ETF |
26.25K |
77.95K |
0.11% |
2023-05-30 |
Vanguard Russell 2000 Index Fund |
17.05K |
50.64K |
0.07% |
2023-05-30 |
Fidelity Total Market Index Fund |
12.00K |
35.63K |
0.05% |
Dividend |
Date |
0.001 |
2012-04-02 |
0.0016 |
2006-01-12 |
0.0005 |
2003-12-18 |
Split |
Date |
1 : 30 |
2023-04-12 |
1 : 40 |
2016-05-02 |
5 : 1 |
2014-07-29 |
2 : 1 |
2006-03-30 |